Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY: MRK )

131.15 +0.43 (+0.33%)
Streaming Delayed Price Updated: 12:07 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
82 83 Next >
January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump
Are you looking to profit from the January effect? Here are three under-the-radar stocks poised for a new year's jump. 
Via InvestorPlace
MarketBeat Week in Review – 12/18 - 12/22
The torrid stock market rally cooled down a little bit heading into the extended holiday weekend; we wish you a Happy Holiday season with friends and family 
Via MarketBeat
Topics Economy
Exposures Interest Rates
7 Small-Cap Stocks That Wall Street Loves for Good Reason
The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading 
Via InvestorPlace
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
7 Best Dow Jones Stocks to Buy for Conservative Investors
With many vagaries still surrounding the market, the best Dow Jones stocks for conservative investors offers a safer approach. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or... 
Via Benzinga
Exposures Product Safety
Merck Provides U.S. Regulatory Update on Gefapixant
From Merck & Co., Inc.
Via Business Wire
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
From Merck & Co., Inc.
Via Business Wire
Better Dividend Stock: Bristol Myers Squibb or Merck?
These two pharma stocks have sizable dividend yields. Which is the better buy right now? 
Via The Motley Fool
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
From Merck & Co., Inc.
Via Business Wire
Jim Cramer Slams FTC Chair Lina Khan's Policies For Hampering Investor Returns: 'One-Woman Wrecking Crew For Your Stock Portfolio'
He posits that such actions have negatively impacted stock valuations. 
Via Benzinga
C4 Therapeutics blasts off: what's next?
As the market soars to new heights, C4 Therapeutics (NASDAQ: CCCC) has become the latest small-cap stock to explode higher in price and volume. 
Via MarketBeat
Topics ETFs
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
Analysts think these beaten-down stocks could rebound strongly in the new year. 
Via The Motley Fool
Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?
Moderna's personalized cancer vaccine candidate just delivered excellent clinical trial results. 
Via The Motley Fool
Contaminated Vaccines: FDA Reportedly Finds Cleaning And Expiry Lapses At Moderna's Massachusetts Facility
The U.S. Food and Drug Administration (FDA) identified several quality control issues at the primary manufacturing facility of Moderna Inc. (NASDAQ: MRNA)  
Via Benzinga
Exposures Product Safety
FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
What's Going On With C4 Therapeutics Stock?
C4 Therapeutics, Inc. (NASDAQ: CCCC) shares are trading higher Friday, and the stock has gained more than 350% over the past five days. 
Via Benzinga
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a... 
Via Benzinga
Exposures Product Safety
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
From Merck & Co., Inc.
Via Business Wire
MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer
Moderna is in focus after reporting positive results for its cancer treatment today, with MRNA stock surging more than 9%. 
Via InvestorPlace
Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted'
Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's promising new cancer vaccine developed in 
Via Benzinga
Why Is Moderna (MRNA) Stock Up 11% Today?
Moderna stock is on the rise Thursday as investors in MRNA react to positive results from a skin cancer vaccine in a Phase 2b trial. 
Via InvestorPlace
Moderna Stock Is Soaring Today - Here's Why
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940), an investigational individualized... 
Via Benzinga
Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%; Will Shares Jump?
Moderna and Merck are already working on a Phase 3 study, but these are long-running tests. 
Via Investor's Business Daily
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
Via ACCESSWIRE
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen. 
Via The Motley Fool
Dow Jones Skyrockets To Record Heights, Shatters 37,000 Mark, Fueled By Fed's Dovish Stance
The 30 largest blue-chip stocks in the Dow Jones Industrial Average surged to unprecedented highs following the Federal Reserve's decision to keep interest rates steady. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
What's Going On With Moderna Stock Today?
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and  
Via Benzinga
Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?
C4 Therapeutics stock is rising higher on Tuesday as investors in CCCC shares celebrate a new collaboration agreement with Merck. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
82 83 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.